US 12,233,047 B2
Pharmaceutical combination and use thereof
Yifan Zhai, Suzhou (CN); Dajun Yang, Suzhou (CN); Douglas Dong Fang, Suzhou (CN); and Qiuqiong Tang, Suzhou (CN)
Assigned to ASCENTAGE PHARMA (SUZHOU) CO., LTD., (CN); and ASCENTAGE PHARMA GROUP CORP LIMITED, (CN)
Appl. No. 17/421,131
Filed by ASCENTAGE PHARMA (SUZHOU) CO., LTD., Suzhou (CN); ASCENTAGE PHARMA GROUP CORP LIMITED, Central (CN); and GUANGZHOU HEALTHQUEST PHARMA CO., LTD., Guangzhou (CN)
PCT Filed Jul. 16, 2020, PCT No. PCT/CN2020/102275
§ 371(c)(1), (2) Date Jul. 7, 2021,
PCT Pub. No. WO2021/013028, PCT Pub. Date Jan. 28, 2021.
Claims priority of application No. PCT/CN2019/096843 (WO), filed on Jul. 19, 2019; and application No. 202010598136.2 (CN), filed on Jun. 28, 2020.
Prior Publication US 2022/0142975 A1, May 12, 2022
Int. Cl. A61K 31/403 (2006.01); A61K 31/437 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/403 (2013.01) [A61K 31/437 (2013.01); A61P 35/02 (2018.01)] 20 Claims
 
1. A method for treating acute myeloid leukemia in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of substance M and substance N, wherein the substance M is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; and the substance N is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.